On November 21st. OPIC, USST made great progress in cerebrovascular. Several achievements from such RCTs as PROTECT-MT and MAGIC-M headed by OPIC team were respectively released in The Lancet and the New England Journal of Medicine. This research achievement fully reflects the academic influence of the university in related fields, not only showcasing OPIC's continuous innovation in treatment of cerebrovascular disease, but also providing important empirical foundation and theoretical support for clinical practice and academic development in this field.
Since the establishment, OPIC has devoted itself to basic research and clinical transformation of cerebrovascular. The research in ROTTEC-MT is the world's first randomized controlled trial (RCT) research project aimed at addressing the issue of thrombectomy procedures for acute ischemic stroke, involving a total of 28 relevant institutions. The results revealed that making non-blood flow control for thrombectomy could cut operation time, lower mortality rate, and secure better clinical prognosis. This research achievement will imposed a profound impact on the standardization of arterial thrombectomy procedures. While the MAGIC-MT study focuses on the clinical challenge of non-acute subdural hematoma. The results indicated that auxiliary meningeal artery embolization (MMAE), as an innovative minimally invasive treatment, could significantly reduce the hematoma progression rate of symptomatic non-acute subdural hematoma patients without drilling. In addition, MMAE reduced the recurrence and progression rates of all patients with symptomatic non-acute subdural hematoma. This research is the world's largest randomized controlled trial (RCT) with a sample size for the treatment of non-acute subdural hematoma with middle meningeal artery embolization, providing a new minimally invasive treatment for patients worldwide, and will benefit them with the "Chinese answer".
Dedicated to innovation in pan vascular devices, OPIC adheres to the core philosophy of "From the doctors, by the engineers, for the patients", and committed itself to transforming cutting-edge scientific technology into clinical solutions that benefit patients. In the future, Driven by innovation OPIC will continue to cultivate more medical research talents with international vision, enhance China's influence in the global medical research field, and facilitate the development and breakthroughs of international medical technology.
